0.85
-0.069(-7.54%)
Currency In USD
| Previous Close | 0.91 |
| Open | 0.82 |
| Day High | 0.86 |
| Day Low | 0.77 |
| 52-Week High | 4.74 |
| 52-Week Low | 0.36 |
| Volume | 3.68M |
| Average Volume | 15.83M |
| Market Cap | 101.18M |
| PE | -0.43 |
| EPS | -1.95 |
| Moving Average 50 Days | 0.91 |
| Moving Average 200 Days | 1.02 |
| Change | -0.07 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $40.51 as of March 12, 2025 at a share price of $0.846. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $181.91 as of March 12, 2025 at a share price of $0.846.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1
GlobeNewswire Inc.
Mar 05, 2025 12:05 PM GMT
New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against LP.8.1 Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitute the majority of current national SARS-CoV-2 va
FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients
GlobeNewswire Inc.
Feb 24, 2025 12:05 PM GMT
FDA’s reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent antiviral activity to past, highly effective, pre
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
GlobeNewswire Inc.
Feb 10, 2025 12:00 PM GMT
WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The pr